论文部分内容阅读
目的探讨不同剂量疏血通对冠心病心绞痛的疗效与安全性。方法 90例资料齐全的冠心病心绞痛患者,分为对照组(A组)、疏血通6 mL治疗组(B组)、疏血通10 mL治疗组(C组),三组患者均给予正规基础治疗(包括ACEI、β-受体阻滞剂、硝酸酯类、阿司匹林、调脂药等),比较三组在治疗前后心绞痛发作次数、持续时间,非致死性心肌梗死,心源性死亡,心电图改变等指标。结果 B组和C组治疗后在心绞痛发作次数、持续时间、心电图改变等方面均优于A组(P<0.05);而C组在各项指标上优于B组(P<0.05)。结论疏血通可显著减少冠心病心绞痛发作次数,缩短发作时间,改善心电图缺血表现,较大剂量疏血通疗效更好,且安全无副作用。
Objective To investigate the efficacy and safety of different doses of Shuxuetong on angina pectoris of coronary heart disease. Methods Ninety patients with angina pectoris were divided into control group (A group), Shuxuetong 6 mL treatment group (B group) and Shuxuetong 10 mL treatment group (C group). All three groups were given regular Basic treatment (including ACEI, β-blockers, nitrates, aspirin, lipid-lowering drugs, etc.) were compared before and after treatment of angina pectoris times, duration, non-fatal myocardial infarction, cardiac death, ECG changes and other indicators. Results After treatment, the number of angina pectoris, duration, ECG changes in group B and group C were better than those in group A (P <0.05), while those in group C were better than those in group B (P <0.05). Conclusion Shuxuetong can significantly reduce the incidence of angina pectoris, shorten the attack time, improve the performance of ECG ischemia, the effect of larger doses of Shuxuetong better and safe without side effects.